- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Dr. Howard A. Fields joins the Scientific Advisory Board after retiring from the CDC as Team Leader of the Assay Development and Cell Culture Team within the Division of Viral Hepatitis
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Dr. Howard A. Fields has joined the Scientific Advisory Board (SAB) of NanoViricides, Inc. "We are taking steps to accelerate our Hepatitis C antiviral nanoviricides program," said Eugene Seymour, MD, MPH, CEO of the Company, adding "We are delighted to have Dr Fields, an internationally renowned authority, join our SAB to guide this program."
"I have been very excited by the nanoviricides technology," said Dr. Fields about his joining the Company's SAB, adding, "I believe it represents the next step beyond immunotherapeutics, and has great potential."
Dr. Fields is a distinguished international expert in Viral Hepatitis. During his thirty-two year career at the CDC, he was the Team Leader of Assay Development and Cell Culture Team within the Division of Viral Hepatitis at the Centers for Disease Control and Prevention (CDC), where he led the research on all hepatitis viruses including Hepatitis C virus, and Hepatitis B virus from 2002 until his recent retirement. Prior to that, he was Chief, Molecular and Immunodiagnostic Section (MIDS), Hepatitis Branch, Division of Viral and Rickettsial Diseases. From 1990 to 1994, he was given the responsibility for the conduct of the WHO Collaborating Centre for Reference and Research on Viral Hepatitis at CDC particularly regarding technology transfer issues.
Dr Fields holds six US and international patents, with additional six patent applications pending. He has more than 150 research publications. Dr. Fields holds a PhD in Microbiology from the University of New Hampshire.
About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, and dengue fever, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
For more information, please click here
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017